GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

Key TakeawaysBlujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.

“The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific Officer, GSK. “We are proud to have developed ...

Blujepa, the brand name for gepotidacin ... and half of all women experience a UTI in their lifetime, with some 30% of women suffering from recurrent episodes. “For many, UTIs can be a burden ...